Don't let schooling interfere with your education."- Mark Twain
Busted IPO Forum model portfolio holding Karyopharm Therapeutics (KPTI) reported Q4 results late this week. This report shows the company continues to make impressive progress with its initial rollout with recently approved XPOVIO. The results might have gotten a bit overlooked by the market as we saw a torrent of fourth-quarter reports this week. However, this progress should not go unnoticed so we will take a deeper look at Karyopharm's fourth quarter and what is ahead for this intriguing 'Tier 3'